Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Grupo Español Multidisciplinar de Melanoma
With
GlaxoSmithKline
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who have received at least one dose of dabrafenib or combination with trametinib as part of a compassionate use for the treatment of metastatic melanoma, with deadline the start of treatment the April 30, 2014.
You may not be if
Patients with a history not available.
Clareo Health | Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain
